110 related articles for article (PubMed ID: 21396490)
1. Identification of prognostic protein biomarkers in childhood acute lymphoblastic leukemia (ALL).
Jiang N; Kham SK; Koh GS; Suang Lim JY; Ariffin H; Chew FT; Yeoh AE
J Proteomics; 2011 May; 74(6):843-57. PubMed ID: 21396490
[TBL] [Abstract][Full Text] [Related]
2. BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia.
Jiang N; Koh GS; Lim JY; Kham SK; Ariffin H; Chew FT; Yeoh AE
Exp Hematol; 2011 Mar; 39(3):321-9, 329.e1-3. PubMed ID: 21130142
[TBL] [Abstract][Full Text] [Related]
3. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.
Manabe A; Ohara A; Hasegawa D; Koh K; Saito T; Kiyokawa N; Kikuchi A; Takahashi H; Ikuta K; Hayashi Y; Hanada R; Tsuchida M;
Haematologica; 2008 Aug; 93(8):1155-60. PubMed ID: 18519521
[TBL] [Abstract][Full Text] [Related]
4. Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia.
Hongo T; Yamada S; Yajima S; Watanabe C; Fujii Y; Kawasaki H; Yazaki M; Hanada R; Horikoshi Y
Int J Hematol; 1999 Dec; 70(4):268-77. PubMed ID: 10643153
[TBL] [Abstract][Full Text] [Related]
5. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol.
Igarashi S; Manabe A; Ohara A; Kumagai M; Saito T; Okimoto Y; Kamijo T; Isoyama K; Kajiwara M; Sotomatsu M; Sugita K; Sugita K; Maeda M; Yabe H; Kinoshita A; Kaneko T; Hayashi Y; Ikuta K; Hanada R; Tsuchida M
J Clin Oncol; 2005 Sep; 23(27):6489-98. PubMed ID: 16170158
[TBL] [Abstract][Full Text] [Related]
6. Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia.
Styczynski J; Piatkowska M; Jaworska-Posadzy A; Czyzewski K; Kubicka M; Kolodziej B; Kurylo-Rafinska B; Debski R; Pogorzala M; Wysocki M
Anticancer Res; 2012 Dec; 32(12):5495-9. PubMed ID: 23225457
[TBL] [Abstract][Full Text] [Related]
7. [Identification of new markers for childhood acute lymphoblastic leukemia by MALDI-TOF-MS].
Wang D; Lu YQ; Liu YF; Su SF; Li B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1365-9. PubMed ID: 23257434
[TBL] [Abstract][Full Text] [Related]
8. Differential expression pattern of protein markers for predicting chemosensitivity of dexamethasone-based chemotherapy of B cell acute lymphoblastic leukemia.
Dehghan-Nayeri N; Eshghi P; Pour KG; Rezaei-Tavirani M; Omrani MD; Gharehbaghian A
Cancer Chemother Pharmacol; 2017 Jul; 80(1):177-185. PubMed ID: 28585036
[TBL] [Abstract][Full Text] [Related]
9. Changes in the MDR1 gene expression after short-term ex vivo therapy with prednisolone have prognostic impact in childhood acute lymphoblastic leukemia.
Janiszewska H; Styczynski J; Kolodziej B; Wysocki M; Haus O
Ann Hematol; 2009 Dec; 88(12):1193-8. PubMed ID: 19352661
[TBL] [Abstract][Full Text] [Related]
10. Identification of potential predictive markers of dexamethasone resistance in childhood acute lymphoblastic leukemia.
Dehghan-Nayeri N; Rezaei-Tavirani M; Omrani MD; Gharehbaghian A; Goudarzi Pour K; Eshghi P
J Cell Commun Signal; 2017 Jun; 11(2):137-145. PubMed ID: 27778231
[TBL] [Abstract][Full Text] [Related]
11. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
[TBL] [Abstract][Full Text] [Related]
12. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
[TBL] [Abstract][Full Text] [Related]
13. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
Jiang H; Gu LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Xu C; Dong L; Zhou M
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):290-4. PubMed ID: 18554450
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
[TBL] [Abstract][Full Text] [Related]
16. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
[TBL] [Abstract][Full Text] [Related]
18. Resistance to glucocorticoids in childhood acute lymphoblastic leukemia: impact of relationship between ex vivo sensitivity and in vivo concentration on risk factor analysis.
Styczynski J; Koltan A; Wysocki M
Neoplasma; 2006; 53(2):168-73. PubMed ID: 16575474
[TBL] [Abstract][Full Text] [Related]
19. [Relationship between the bone marrow cell proliferation and the prognosis in childhood acute lymphoblastic leukemia].
Zheng H; Zhao X; Geng L
Zhonghua Xue Ye Xue Za Zhi; 1999 Jan; 20(1):7-9. PubMed ID: 11498846
[TBL] [Abstract][Full Text] [Related]
20. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
